Clinigen Group Plc (CLIGF) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Clinigen Group Plc (NASDAQ:CLIGF) from a hold rating to a buy rating in a research note published on Tuesday. Zacks Investment Research currently has $15.00 price objective on the stock.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of Clinigen Group Plc (NASDAQ CLIGF) traded up 7.34% during mid-day trading on Tuesday, reaching $13.90. 3,637 shares of the company’s stock traded hands. Clinigen Group Plc has a 12-month low of $8.70 and a 12-month high of $13.90. The company has a market cap of $1.60 billion and a P/E ratio of 85.80.

WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at

Get a free copy of the Zacks research report on Clinigen Group Plc (CLIGF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply